Importance: Direct oral anticoagulant (DOAC)-associated intracranial hemorrhage (ICH) has high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH are limited.
Objective: To evaluate the safety and outcomes of DOAC reversal agents among patients with ICH.